Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05888246
Other study ID # Hangzhounuochi
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 7, 2022
Est. completion date May 14, 2022

Study information

Verified date July 2023
Source Hangzhou Nuochi Life Science Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A prospective and observational clinical study of measuring the range of cardiac magnetic parameters in healthy people with the magnetocardiogram manufactured by Hangzhou Nuochi Life Science Co., LTD


Description:

This study is a prospective and observational study on the collection of cardiac magnetic signals from healthy subjects by magnetocardiogram. It is expected that 412 subjects will be examined by magnetocardiography, and the range of parameters related to magnetocardiography in healthy subjects will be reported.


Recruitment information / eligibility

Status Completed
Enrollment 412
Est. completion date May 14, 2022
Est. primary completion date May 14, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Healthy people aged 18-70 years old; 2. Subjects receiving physical examination in physical examination institutions, or in other departments other than heart disease (such as orthopedics, gynecology, etc.), or in cardiology department, excluded from coronary heart disease; 3. No history of coronary heart disease; 4. ECG did not indicate myocardial ischemia or infarction; 5. Sinus rhythm without arrhythmia; 6. The subject or the subject's legal representative has been informed of the nature of the study, understands the purpose of the clinical study, voluntarily participates in the study and signs the informed consent. Exclusion Criteria: 1. Acute coronary syndrome requires emergency PCI treatment, and it is estimated that magnetic cardiogram examination will affect the timing of emergency PCI surgery; 2. Subjects with metal implants in the thoracic cavity (including the heart cavity), such as those who have received pacemaker therapy or cardiac resynchronization therapy (CRT, CRT-D) or implantable cardioverter defibrillator (ICD) implantation, or those who have received metal heart valve implantation; 3. There is hemodynamic instability, which is defined as systolic blood pressure < 80mmHg, or cardiogenic shock; Or need vasoactive drug therapy; Intra-aortic balloon counterpulsation may be required; Or other hemodynamic support devices; As syndrome; 4. Severe tachycardia (ventricular rate > 150 beats/min), ventricular flutter, ventricular fibrillation and other malignant arrhythmias; 5. Subjects unable to lie flat (supine position); 6. Subjects with mental illness, unconscious or uncontrollable ability; Or claustrophobic subjects; 7. Other circumstances in which the investigator considers the subject inappropriate for participation in the study

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Magnetocardiogram
Magnetocardiogram consists of acquisition and control system (including software) and detection part. Acquisition and control system mainly includes: cabinet, display, host, sensor. The detection part mainly includes: inspection bed, array sensor support frame, magnetic shielding equipment.

Locations

Country Name City State
China The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Hangzhou Nuochi Life Science Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary PR interval PR interval is defined as the position from the starting point of P wave to the starting point of QRS wave after the superposition of 36 channels in the magnetocardiogram (butterfly diagram). 24 hours
Primary QRS interval QRS interval is defined as the time (ms) from the beginning of QRS to the end of QRS after the stacking of 36 channels in the magnetocardiogram (butterfly diagram). 24 hours
Primary QT interval QT interval is defined as the time (ms) from the beginning of Q wave to the end of T wave after the stacking of 36 channels in the magnetocardiogram (butterfly diagram). 24 hours
Primary Corrected QT interval The corrected QT interval was defined as the QTC interval (ms) after the stacking of 36 channels in the magnetocardiogram (butterfly diagram). QTc = QT/(RR^0.5), RR is the average RR interval calculated by cardiac magnetic waveform, QT is QT interval. 24 hours
Primary The magnetic field intensity parameter (R/T ratio) The magnetic field intensity parameter (R/T ratio) is defined as the ratio of the maximum magnetic field intensity of the r-wave vertex to the T-wave vertex of the magnetocardiogram calculated based on the isomagnetic map. 24 hours
Primary Maximum current vector angle (MCV angle) The Angle of the maximum current vector was measured at the vertex of QRS and T wave respectively. 24 hours
Primary Maximum current vector amplitude (MCV amplitude) The amplitude of the maximum current vector was measured at the vertex of QRS wave and T wave respectively. 24 hours
Primary Total current vector angle (TCV angle) TCV represents the total current vector, which is the sum of all current vectors of 36 channels in the magnetocardiogram. First calculate the vector sum of the 36 channels, and finally calculate the angles. 24 hours
Primary Total current vector amplitude (TCV amplitude) TCV represents the total current vector, which is the sum of all current vectors of 36 channels in the magnetocardiogram. First calculate the vector sum of the 36 channels, and finally calculate the amplitude. 24 hours
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05410795 - Establishment and Verification of Pancreatic Volume Formula Based on Imaging
Not yet recruiting NCT00966862 - The Glycemic Effect of Taking a Supplementation of Orange Juice With Fibers Phase 1/Phase 2
Not yet recruiting NCT00966784 - The Effect of 2 Months Daily Supplementation of Orange Juice With Fibers Phase 1/Phase 2
Recruiting NCT04213105 - Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Prolia® in Healthy Adults Phase 1
Completed NCT01840982 - The Effects of Mixed Grain on Blood Glucose and Insulin in Healthy Male N/A
Not yet recruiting NCT05619393 - Comparison of Kinematic Movements Between ACL Deficiency With ACL Reconstruction and Healthy People N/A
Recruiting NCT05095753 - Data Collection of Heart Rate and Blood Pressure
Enrolling by invitation NCT05140577 - Reliability and Validity of the Evaluation of Hip Abductors Strength (RAVEHABDS)
Not yet recruiting NCT04319211 - Effects of Social Isolation From Coronavirus; on Physical Activity, Quality of Life and Stress
Recruiting NCT01261195 - Establishment of Vascular Permeability Model for Research Purpose by Human Umbilical Vascular Endothelial Cells N/A
Not yet recruiting NCT01079585 - The Effect of 40gr Okara on Gastric Emptying N/A
Completed NCT01476865 - Articular Sonography: Healthy Subjects Versus Rheumatoid Arthritis Patients N/A
Not yet recruiting NCT01075568 - The Satiety Effect After Okara Compared to Porridge Eating N/A
Completed NCT04389255 - Developing a Balance Assessment System
Not yet recruiting NCT06303635 - Safety of UFRJvac, Trivalent COVID-19 Vaccine
Recruiting NCT03293056 - HIIH Versus HMC: Randomized Clinical Trial N/A
Not yet recruiting NCT06186635 - Comparison of Traditional and Artificial Intelligence-Assisted Yoga N/A
Recruiting NCT04545359 - Study on Neurofeedback and Relaxation N/A
Not yet recruiting NCT06006182 - The Effects of Freeze-Dried Whole Grape Powder on Chronic Disease and Cardiovascular Risk Factors-a Pilot Study N/A
Completed NCT03651947 - Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults Phase 1